Original Research

Incidental Findings of Pulmonary and Hilar Malignancy by Low-Resolution Computed Tomography Used in Myocardial Perfusion Imaging

Author and Disclosure Information

 

References

Limitations

The study was retrospective in nature and limited by its small number of patients. The CT modality used in the study also has limitations, including low resolution, respiratory motion artifacts, and scans that did not include the entire chest area. Therefore, small and apical lesions may have been missed. However, both sets of CT at rest and after stress were reviewed to reduce or minimize the effects of respiratory motion artifacts. The true prevalence or incidence of pulmonary/hilar malignancies may have been higher than reported here. Our study population of veterans may not be representative of the general population with regards to gender (as most of our veteran patient population are of male gender, vs general population), smoking history, or lung cancer risk, thus the results should be interpreted with caution.

Conclusion

Low-resolution CTs used for attenuation correction during cardiac MPI should be routinely reviewed and interpreted by a physician or radiologist skilled in CT interpretation in order to identify incidental findings of pulmonary/hilar malignancy. This would require close collaboration between cardiologists and radiologists in the field to ensure unfragmented and high-quality patient care.

Acknowledgements

We want to thank all the staffs in cardiology and radiology department on both campuses for their dedication for our patients. Special thanks to Laura Knox, Radiation Safety Officer, Nuclear Medicine Supervisor for her technical assistance.

Pages

Recommended Reading

Distress and Factors Associated with Suicidal Ideation in Veterans Living with Cancer (FULL)
Federal Practitioner
Radiotherapeutic Care of Patients With Stage IV Lung Cancer with Thoracic Symptoms in the Veterans Health Administration (FULL)
Federal Practitioner
Atrial Fibrillation and Bleeding in Patients With Chronic Lymphocytic Leukemia Treated with Ibrutinib in the Veterans Health Administration (FULL)
Federal Practitioner
Predicting outcomes in therapy-related AML
Federal Practitioner
Survival benefit with nivolumab extends to 5 years in NSCLC
Federal Practitioner
Is it time for universal genetic testing in colorectal cancer?
Federal Practitioner
To stay: Two more cancer indications with ‘dangling approvals’
Federal Practitioner
Superior survival with sintilimab in squamous NSCLC
Federal Practitioner
A Pivotal Moment in Cancer Surgery, Captured on Film
Federal Practitioner
Success in LGBTQ+ medicine requires awareness of risk
Federal Practitioner